Charles University
Efficacy and Safety of Switching from Ranibizumab to Brolucizumab in Wet Age-Related Macular Degeneration
Research findings have been presented on the efficacy and safety of switching from ranibizumab to brolucizumab in the treatment of wet age-related macular degeneration (wAMD). A multicenter retrospective study included patients aged 50 years with active wAMD, and the results showed that switching to brolucizumab reduced central retinal thickness (CRT)